CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $) In Thousands, except Share data, unless otherwise specified	Total	Common Shares	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Valeant Pharmaceuticals International, Inc. Shareholders' equity	Noncontrolling Interest	Comprehensive Loss
Balance at Dec. 31, 2010	$ 4,911,096	$ 5,251,730	$ 495,041	$ (934,511)	$ 98,836	$ 4,911,096
Balance (in shares) at Dec. 31, 2010		302,449,000
Increase (Decrease) in Shareholders' Equity
Settlement of Convertible Notes	225,983	892,000	(225,971)	(440,046)		225,983
Settlement of Convertible Notes (in shares)		17,783,000
Repurchase of equity component of 5.375% Convertible Notes	(414,003)		(33,169)	(380,834)		(414,003)
Common shares issued under share-based compensation plans	41,717	121,099	(79,382)			41,717
Common shares issued under share-based compensation plans (in shares)		4,338,000
Settlement of call options	(66,863)	(36,343)	11,072	(41,592)		(66,863)
Settlement of call options (in shares)		(2,999,000)
Repurchase of common shares	(639,242)	(264,865)		(374,377)		(639,242)
Repurchase of common shares (in shares)		(15,200,000)
Share-based compensation	94,023		94,023			94,023
Employee withholding taxes related to share-based awards	(37,702)		(19,211)	(18,491)		(37,702)
Tax benefits from stock options exercised	26,414		26,414			26,414
Reclassification of deferred share units	9,271		9,271			9,271
Noncontrolling interest from business combinations	58,555						58,555
Acquisition of noncontrolling interest	(58,320)		(1,971)			(1,971)	(56,349)
Total before comprehensive income (loss)	4,150,929	5,963,621	276,117	(2,189,851)	98,836	4,148,723	2,206
Total before comprehensive income (loss) (in shares)		306,371,000
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	159,559
Comprehensive loss:
Net (loss) income	159,559			159,559		159,559		159,559
Less: Net income attributable to noncontrolling interest	0
Other comprehensive income (loss)	(378,452)
Other Comprehensive Income (Loss), Net of Tax					(378,452)	(378,452)	(2,206)	(380,658)
Comprehensive (loss) income	(218,893)					(218,893)	(2,206)	(221,099)
Balance at Dec. 31, 2011	3,929,830	5,963,621	276,117	(2,030,292)	(279,616)	3,929,830
Balance (in shares) at Dec. 31, 2011		306,371,000
Increase (Decrease) in Shareholders' Equity
Settlement of Convertible Notes	(43,768)		(175)	(43,593)		(43,768)
Repurchase of equity component of 5.375% Convertible Notes	(2,862)		(180)	(2,682)		(2,862)
Common shares issued under share-based compensation plans	23,023	79,371	(56,348)			23,023
Common shares issued under share-based compensation plans (in shares)		2,747,000
Repurchase of common shares	(280,724)	(102,340)		(178,384)		(280,724)
Repurchase of common shares (in shares)		(5,257,000)
Share-based compensation	66,236		66,236			66,236
Employee withholding taxes related to share-based awards	(31,073)		(31,073)			(31,073)
Tax benefits from stock options exercised	12,541		12,541			12,541
Total before comprehensive income (loss)	3,673,203	5,940,652	267,118	(2,254,951)	(279,616)	3,673,203
Total before comprehensive income (loss) (in shares)		303,861,000
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	(116,025)
Comprehensive loss:
Net (loss) income	(116,025)			(116,025)		(116,025)		(116,025)
Less: Net income attributable to noncontrolling interest	0
Other comprehensive income (loss)	160,220
Other Comprehensive Income (Loss), Net of Tax					160,220	160,220		160,220
Comprehensive (loss) income	44,195					44,195		44,195
Balance (including portion attributable to non-controlling interest) at Dec. 31, 2012	3,717,398
Balance at Dec. 31, 2012	3,717,398	5,940,652	267,118	(2,370,976)	(119,396)	3,717,398
Balance (in shares) at Dec. 31, 2012	303,861,272	303,861,000
Increase (Decrease) in Shareholders' Equity
Issuance of common stock	2,306,880	2,306,880				2,306,880
Issuance of common stock (in shares)		27,562,000
Common shares issued under share-based compensation plans	6,510	67,865	(61,355)			6,510
Common shares issued under share-based compensation plans (in shares)		2,339,000
Repurchase of common shares	(55,629)	(14,218)		(41,411)		(55,629)
Repurchase of common shares (in shares)		(725,000)
Share-based compensation	45,478		45,478			45,478
Employee withholding taxes related to share-based awards	(46,588)		(46,588)			(46,588)
Tax benefits from stock options exercised	24,200		24,200			24,200
Noncontrolling interest from business combinations	113,896						113,896
Noncontrolling interest distributions	(2,101)						(2,101)
Total before comprehensive income (loss)	6,110,044	8,301,179	228,853	(2,412,387)	(119,396)	5,998,249	111,795
Total before comprehensive income (loss) (in shares)		333,037,000
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	(866,142)			(866,142)
Comprehensive loss:
Net (loss) income	(863,669)					(866,142)		(863,669)
Less: Net income attributable to noncontrolling interest	2,473
Other comprehensive income (loss)	(13,053)
Other Comprehensive Income (Loss), Net of Tax					(13,384)	(13,384)	331	(13,053)
Comprehensive (loss) income	(876,722)					(879,526)	2,804	(876,722)
Balance (including portion attributable to non-controlling interest) at Dec. 31, 2013	5,233,322	8,301,179	228,853	(3,278,529)	(132,780)	5,118,723	114,599
Balance at Dec. 31, 2013	$ 5,118,723
Balance (in shares) at Dec. 31, 2013	333,036,637	333,037,000